Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 5/20 | 0.55 |
| ▸ | ACHE | P22303 | 4/20 | 0.55 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.47 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19971615 | 1.00 | BCHE (0.55) | BCHEACHEFUCA1S1PR5S1PR1 | |
| SCHEMBL19971617 | 1.00 | BCHE (0.55) | BCHEACHEFUCA1S1PR5S1PR1 | |
| SCHEMBL4237606 | 0.83 | CHRM2 (0.48) | BCHEACHEFUCA1S1PR5S1PR1 | |
| SCHEMBL18517359 | 0.82 | BCHE (0.51) | BCHEACHEFUCA1S1PR5S1PR1 | |
| SCHEMBL19971611 | 0.82 | BCHE (0.51) | BCHEACHEFUCA1S1PR5S1PR1 | |
| SCHEMBL19971612 | 0.82 | BCHE (0.51) | BCHEACHEFUCA1S1PR5S1PR1 | |
| SCHEMBL4245563 | 0.78 | ACHE (0.49) | BCHEACHEMAOB | |
| SCHEMBL4617491 | 0.77 | CHRM3 (0.48) | BCHEACHEFUCA1S1PR5S1PR1 | |
| SCHEMBL1014405 | 0.76 | FUCA1 (0.53) | BCHEACHEFUCA1S1PR5S1PR1 | |
| SCHEMBL4619115 | 0.75 | CHRM3 (0.46) | BCHEACHEFUCA1S1PR5S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190092781-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2019-03-28 | — | — | US | disclosed |
| US-20190023716-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2019-01-24 | — | — | US | disclosed |
| US-20180237449-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2018-08-23 | — | — | US | disclosed |
| US-9944613-B2 | Fumagillol spirocyclic compounds and fused bicyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20180079737-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079737-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FOLH1, FAP | BCHE 171/4885ACHE 680/4885FUCA1 166/4885 |
| US-20180237449-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FOLH1, FAP | BCHE 171/4885ACHE 680/4885FUCA1 166/4885 |
| US-20190092781-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FOLH1, FAP | BCHE 171/4885ACHE 680/4885FUCA1 166/4885 |
| US-20190023716-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FOLH1, FAP | BCHE 171/4885ACHE 680/4885FUCA1 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.